Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer

Sat, 06/01/2019 - 6:41pm

Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data...

      Related Stories 

Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space

Sat, 06/01/2019 - 10:08am

Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast...

      Related Stories 

BI Inks Second Obesity Pact With Denmark’s Gubra

Fri, 05/31/2019 - 8:37am

The German group has signed a second deal with Gubra to develop poly-agonist peptides for obesity that could be worth...

      Related Stories 

Kiadis Raises €28m As Cell Therapy Nears Commercialization

Fri, 05/31/2019 - 7:51am

The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of...

      Related Stories 

Nanobiotix CEO: Curadigm Spin-Out Platform Could ‘Redefine’ Drug-Body Balance

Fri, 05/31/2019 - 7:09am

Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity...

      Related Stories 

VIDEO: BIO-Europe Spring 2019: Finally, Paion Teeters On Cusp Of Commercialization

Fri, 05/31/2019 - 1:57am

Wolfgang Söhngen, CEO and founder of Paion, discusses the company’s anesthetic/sedative, remimazolam, which has been filed for approval in China...

      Related Stories 

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

Thu, 05/30/2019 - 2:08pm

Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also...

      Related Stories 

Product Launches To Plan For In 2020

Thu, 05/30/2019 - 8:14am

A sizeable group of key late-stage products have the potential to reach their first markets in 2020, according to a...

      Related Stories 

Genmab Plots $500m Nasdaq IPO

Thu, 05/30/2019 - 7:53am

Some 20 years after its birth, the Danish biotech has decided the time is right to go west and raise...

      Related Stories 

Mereo Posts Early Upbeat Look At Brittle Bone Data For Setrusumab

Thu, 05/30/2019 - 7:06am

The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead...

      Related Stories 

INFOGRAPHIC: Two Years Of Artificial Intelligence Deals: A Pharma Snapshot

Thu, 05/30/2019 - 2:00am

INFOGRAPHIC: major alliance deals focused on artificial intelligence and machine learning, signed by pharmaceutical companies over the past two years.

      Related Stories 

Legal Challenge To First Japan Rituxan Biosimilar Dismissed

Wed, 05/29/2019 - 11:15pm

First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai...

      Related Stories